Saikosaponin A
Based on 5 publication(s) in Google Scholar
Saikosaponin A is the main active ingredient in Bupleurum chinense, which can regulate lipid metabolism and promote cholesterol efflux in early atherosclerosis. In addition, Saikosaponin A may also serve as a potential peroxisome proliferator-activated receptor γ (PPAR-γ) agonist, significantly promoting the expression of PPAR-γ. Saikosaponin A can be used in the study of hyperlipidemic pancreatitis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.31%
- CAS No.: 20736-09-8
- Formule: C42H68O13
- Masse moléculaire:780.98
-
Stockage:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Saikosaponin A
More
Customer Validation & Images
-
RT-PCR
-
WB
-
Histological Imaging/Staining
-
IP
-
IF
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A-375 | IC50 |
23.9 μM
Compound: 1
|
Cytotoxicity against human A375 cells after 48 hrs by SRB assay
Cytotoxicity against human A375 cells after 48 hrs by SRB assay
|
[PMID: 19467877] |
| A549 | IC50 |
14.54 μM
Compound: 8
|
Cytotoxicity against human A549 cells assessed as induction of cell death incubated for 2 days by MTT assay
Cytotoxicity against human A549 cells assessed as induction of cell death incubated for 2 days by MTT assay
|
[PMID: 26259802] |
| A549 | IC50 |
17.7 μM
Compound: 1
|
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
|
[PMID: 19467877] |
| ACHN | IC50 |
>50 μM
Compound: 1
|
Cytotoxicity against human ACHN cells after 48 hrs by SRB assay
Cytotoxicity against human ACHN cells after 48 hrs by SRB assay
|
[PMID: 19467877] |
| Bcap37 | IC50 |
13.96 μM
Compound: 8
|
Cytotoxicity against human Bcap37 cells assessed as induction of cell death incubated for 2 days by MTT assay
Cytotoxicity against human Bcap37 cells assessed as induction of cell death incubated for 2 days by MTT assay
|
[PMID: 26259802] |
| C32 | IC50 |
43.5 μM
Compound: 1
|
Cytotoxicity against human C32 cells after 48 hrs by SRB assay
Cytotoxicity against human C32 cells after 48 hrs by SRB assay
|
[PMID: 19467877] |
| Caco-2 | IC50 |
17.9 μM
Compound: 1
|
Cytotoxicity against human Caco-2 cells after 48 hrs by SRB assay
Cytotoxicity against human Caco-2 cells after 48 hrs by SRB assay
|
[PMID: 19467877] |
| COR-L23 | IC50 |
0.6 μM
Compound: 1
|
Cytotoxicity against human COR-L23 cells after 48 hrs by SRB assay
Cytotoxicity against human COR-L23 cells after 48 hrs by SRB assay
|
[PMID: 19467877] |
| Hep 3B2 | IC50 |
13.01 μM
Compound: 8
|
Cytotoxicity against human Hep3B cells assessed as induction of cell death incubated for 2 days by MTT assay
Cytotoxicity against human Hep3B cells assessed as induction of cell death incubated for 2 days by MTT assay
|
[PMID: 26259802] |
| HepG2 | IC50 |
8.34 μM
Compound: 8
|
Cytotoxicity against human HepG2 cells assessed as induction of cell death incubated for 2 days by MTT assay
Cytotoxicity against human HepG2 cells assessed as induction of cell death incubated for 2 days by MTT assay
|
[PMID: 26259802] |
| LNCaP | IC50 |
>50 μM
Compound: 1
|
Cytotoxicity against human LNCAP cells after 48 hrs by SRB assay
Cytotoxicity against human LNCAP cells after 48 hrs by SRB assay
|
[PMID: 19467877] |
| MCF7 | IC50 |
>50 μM
Compound: 1
|
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
|
[PMID: 19467877] |
| MCF7 | IC50 |
18.99 μM
Compound: 8
|
Cytotoxicity against human MCF7 cells assessed as induction of cell death incubated for 2 days by MTT assay
Cytotoxicity against human MCF7 cells assessed as induction of cell death incubated for 2 days by MTT assay
|
[PMID: 26259802] |
| RAW264.7 | IC50 |
>200 μM
Compound: 1
|
Cytotoxicity against mouse RAW264.7 cells by MTT assay
Cytotoxicity against mouse RAW264.7 cells by MTT assay
|
[PMID: 19467877] |
| RAW264.7 | IC50 |
101.8 μM
Compound: 1
|
Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production after 24 hrs by Griess reagent method
Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production after 24 hrs by Griess reagent method
|
[PMID: 19467877] |
Saikosaponin A (5-15 μM, 24 h) did not affect the viability of human osteoarthritis chondrocytes[1].
Saikosaponin A (5-15 μM, 24 h) inhibits IL-1β (HY-P73149)-induced NO and PGE2 production and NF-κB activation[1].
Saikosaponin A (5-15 μM, 24 h) up-regulates the expression of LXRα in a dose-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human osteoarthritis chondrocytes
-
Concentration:5, 10, 15 μM
-
Incubation Time:24 h
-
Result:Inhibited the levels of phosphorylation of NF-κB p65 and IκBα induced by IL-1β.
Up-regulated the expression of LXRα in a dose-dependent manner.
Saikosaponin-A (1-10 mg/kg, i.p, 7 d) enhances the decrease of antioxidant enzymes in intestinal tissue caused by 5-FU[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:5-FU (HY-90006)-induced mucositis in BALB/c mice modle[2]
-
Dosage:1, 5, 10 mg/kg/day, 7 d
-
Administration:injected intraperitoneally (i.p)
-
Result:Reduced villus blunting, crypt cells apoptosis, and inflammatory cell infiltration.
Decreased concentration of GSH, GST, Catalase, and SOD in intestinal tissue.
Chemical Information
-
CAS No. 20736-09-8
-
Appearance Solid
-
Masse moléculaire 780.98
-
Formule C42H68O13
-
Color White to off-white
-
SMILES
OC[C@H]1O[C@](O[C@@H]2[C@@H](O)[C@@](O[C@@H]3[C@@](C)(CO)[C@@](CC[C@]4(C)[C@]5([H])C=C[C@@]6(OC7)[C@@]4(C)C[C@H](O)[C@]87[C@@]6([H])CC(C)(C)CC8)([H])[C@]5(C)CC3)([H])O[C@H](C)[C@@H]2O)([H])[C@H](O)[C@@H](O)[C@@H]1O
-
Structure Classification
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Mol Med Rep
Saikosaponin A protects against uremic toxin indole‑3 acetic acid‑induced damage to the myocardium. [Abstract]2023 Sep;28(3):159. PMID: 37417356
Saikosaponin A purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2023 Sep;28(3):159. [Abstract]
Cardiomyocytes were pretreated with Saikosaponin A (SSA) (1, 10 and 30 µmol/L) for 1 h then exposed to IAA (50 µmol/L) for 48 h and mRNA expression levels of ANP, BNP and β-MHC were analyzed by qPCR.
Saikosaponin A purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2023 Sep;28(3):159. [Abstract]
Cardiomyocytes were pretreated with Saikosaponin A (SSA) (30 µmol/L) for 1 h and then exposed to IAA (50 µmol/L) for 48 h and Trim16 protein expression measured by Western blotting.
Saikosaponin A purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2023 Sep;28(3):159. [Abstract]
Representative micrographs (magnification, 10×) of hematoxylin and eosin-stained transverse sections from hearts of control, IAA- and IAA + Saikosaponin A (SSA) (40 mg/kg, i.g.)-treated mice.
Saikosaponin A purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2023 Sep;28(3):159. [Abstract]
Cardiomyocytes were transfected with siTrim16 or scrambled siRNA (siCntl), treated with Saikosaponin A (SSA) (30 µmol/L) for 1 h, then incubated with IAA (50 µmol/L) for 48 h. K48 ubiquitination of RIP2 was measured by immunoprecipitation.
Saikosaponin A purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2023 Sep;28(3):159. [Abstract]
Cell size was observed by immunofluorescence using a troponin antibody treated with Saikosaponin A (SSA) (30 µmol/L).
-
Pestic Biochem Physiol
Mechanistic insights into chlorogenic acid and caffeic acid as novel juvenile hormone antagonists. [Abstract]2025 Dec:215:106655. PMID: 41162045 -
Front Cell Neurosci
Neuroprotective effects of saikosaponin-A in ethanol-induced glia-mediated neuroinflammation, oxidative stress via RAGE/TLR4/NFkB signaling. [Abstract]2025 Aug 18:19:1625362. PMID: 40901367 -
Nutr Neurosci
Protective effect and mechanism of Saikosaponin A against oxidative damage in cochlear hair cells in vitro. [Abstract]2025 Sep 29:1-12. PMID: 41017590 -
Biochem Biophys Res Commun
Engineered MAP30ER: A plant toxin-derived platform for EGFR-Targeted delivery of protein and chemotherapeutic payloads. [Abstract]2025 Aug 30:776:152184. PMID: 40517671
Solvant et solubilité
DMSO : 100 mg/mL (128.04 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.20 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (3.20 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 10 mg/mL (12.80 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (282 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Gao H, et al. Saikosaponin A inhibits IL-1β-induced inflammatory mediators in human osteoarthritis chondrocytes by activating LXRα. Oncotarget. 2017 Sep 30;8(51):88941-88950. [Content Brief]
[2]. Jawad Ali, et al. Mucoprotective effects of Saikosaponin-A in 5-fluorouracil-induced intestinal mucositis in mice model. Life Sci. 2019. [Content Brief]
[3]. Feng P, et al. Saikosaponin a attenuates hyperlipidemic pancreatitis in rats via the PPAR‑γ/NF‑κB signaling pathway[J]. Experimental and therapeutic medicine, 2020, 19(2): 1203-1212. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.2804 mL | 6.4022 mL | 12.8044 mL | 32.0111 mL |
| 5 mM | 0.2561 mL | 1.2804 mL | 2.5609 mL | 6.4022 mL | |
| 10 mM | 0.1280 mL | 0.6402 mL | 1.2804 mL | 3.2011 mL | |
| 15 mM | 0.0854 mL | 0.4268 mL | 0.8536 mL | 2.1341 mL | |
| 20 mM | 0.0640 mL | 0.3201 mL | 0.6402 mL | 1.6006 mL | |
| 25 mM | 0.0512 mL | 0.2561 mL | 0.5122 mL | 1.2804 mL | |
| 30 mM | 0.0427 mL | 0.2134 mL | 0.4268 mL | 1.0670 mL | |
| 40 mM | 0.0320 mL | 0.1601 mL | 0.3201 mL | 0.8003 mL | |
| 50 mM | 0.0256 mL | 0.1280 mL | 0.2561 mL | 0.6402 mL | |
| 60 mM | 0.0213 mL | 0.1067 mL | 0.2134 mL | 0.5335 mL | |
| 80 mM | 0.0160 mL | 0.0800 mL | 0.1601 mL | 0.4001 mL | |
| 100 mM | 0.0128 mL | 0.0640 mL | 0.1280 mL | 0.3201 mL |
Saikosaponin A Related Classifications
HY-N0246 Related Classifications
Powered by Bioz